stockrow
Saturday 7 November 2026
Export MLYS’s income statement to Excel — free account
Mineralys Therapeutics, Inc.
MLYS Healthcare Biotechnology
- EPS
- −331.8%
- Free cash flow
- −7.91%
Quarter to June 2026, against a year earlier
15.35
0.11
+0.72%
Follow MLYS
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
25.50 | 43.76 | 44.33 | 34.46 |
Net Debt/EBITDA |
14.44 | 17.16 | 14.25 | 2.29 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 14.62% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.18 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 1.18 | 1.00 | 0.14 | |
Capex/Depreciation |
0.00 | (1.15) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.41) | (0.56) | (0.48) | (0.38) | |
Cash per Share |
8.41 | 9.71 | 7.80 | 7.81 | |
Shareholders Equity per Share |
8.17 | 9.56 | 7.70 | 6.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.17 | 9.56 | 7.70 | 6.50 | |
Free Cash Flow |
(28.87) | (37.90) | (39.47) | (32.56) | |
Working Capital |
576.28 | 646.27 | 637.75 | 646.48 | |
Capital Expenditures |
— | (0.01) | — | — | |
Net Current Asset Value |
576.28 | 646.27 | 637.75 | 548.87 | |
| Other line items | |||||
Quick Ratio |
25.24 | 43.45 | 43.90 | 34.24 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.41) | (0.56) | (0.48) | (0.38) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.11 | 1.25 | 0.74 | 2.12 | |
Average Assets |
434.10 | 433.85 | 503.90 | 501.79 | |
Average Common Equity |
406.68 | 418.98 | 489.85 | 432.23 | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates